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Figure S1 (Related to Figure 1): Phenotypic characterization of R1 and R2 monocytes and R3 
and P pre-DCs. 
A) FACS analysis of Flt3 and CD115 in BM Ly6C+ cells.  
Anti-Flt3 or isotype staining on MHCII-CD115+SIRPα+Ly6C+ R1 and R2 monocytes and R3 pre-DCs, 
and anti-CD115 or isotype staining on R3 and P (Lin-MHCII-CD115-Flt3+CD11c+) pre-DCs gated on 
Lin-(Ly6G-, CD3e-.NK1.1-, Ter119-, CD19-, CD45RA-) cells. 
B) Phenotype of MHCII+ cells in the BM. F4/80, CD11b and Ly6C expression 
on WT BM Lin-MHCII+ and MHCII- cells. 
C) Cellularity of BM subsets. Percentage of R1, R2 monocytes and R3 pre-DCs in total BM and in 
Lin-CD115+Ly6C+ cells and of CD115-pre-DC (P) in total BM. 
D) R1, R2 and R3 are not ckit+.  
Anti-ckit or isotype control staining of BM Lin-MHCII- cells. R1 and R2 monocytes and R3 pre-DCs 
are gated from Lin-(CD3ɛ-CD19-Ly6G-CD45RA-NK1.1-Ter119-) MHCII-ckit-CD115+Ly6C+ cells. 
E) Phenotype of BM R1 and R2 monocytes and pre-DCs R3 and P. FACS analysis for CD11b and 
CCR2 (solid black lines) expression versus isotype controls (grey shaded) in WT mice. GFP reporter 
expression analyzed in Cx3cr1gfp/+ mice at steady state. Numbers above gates indicate percentage of 
parent population and numbers above histograms indicate mean fluorescence intensity. 
F) Giemsa staining of FACS sorted R1, R2 monocytes and R3 and P Pre-DCs from the BM of WT 
mice. Scale bar=10µm. 
G) Nr4a1 dependency of R1, R2, R3 and P in WT mice. Representative FACS analysis of R1 and R2 
monocyte subsets and pre-DCs- R3 and P, in Nr4a1+/+ and Nr4a1-/- BM. 
H) Analysis of monocytes R1 and R2, and R3 pre-DCs in the blood of Ccr2-/- versus WT mice at 
steady state. 
I) FACS analysis of Ccr2-/- and WT mixed bone marrow chimeras. FACS analysis of CD45.1+ 
(Ccr2+/+) and CD45.1–(Ccr2-/-) cells within R1, R2 monocytes and total pre-DCs in the BM and blood, 
and total cDCs in the spleen of WT reconstituted recipients of Ccr2-/- and WT mixed BM (1:1).  
J) Fate mapping of R1, R2, R3 and P in Zbtb46Cre x ROSAlslYFP mice. YFP expression in R1, R2 
monocytes and pre-DCs R3 and P, in the BM and blood, and CD8α+ and CD11b+ESAM+ and ESAM- 
cDCs in the spleens of Zbtb46Cre x ROSAlslYFP mice.  
K) Expression of cDC and macrophage ImmGen gene signatures in BM R1, R2 and R3 at steady 
state. Relative mRNA expression levels for each gene are depicted according to the color bar shown. 
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Figure S2 (Related to Figure 2):  Transcriptional control of MHCII expression on R1 and R2 
monocytes and R3 pre-DCs. 
A,B) Expression of FcgR and CD209 in R1,R2 and R3. Average values of 3 replicates of microarray 
data of FcgR and CD209 in R1 and R2 monocytes and R3 pre-cDCs (A). Expression of FcgRII/III 
and CD209a versus respective isotype controls as assessed by FACS analysis (B). 
 C) -DCt values in Clusters1-5 and populations R1-3, of Ciita, H2-Aa and H2-Ab as derived from 
single cell multiplex qPCR analysis. 
D) Microarray analysis of MHCII-related genes in R1, R2 and R3. Average values of triplicate 
samples in R1, R2 and R3 are shown for MHCII-related genes. 
E) MHCII expression in blood Lin-CD115+Ly6C+ cells at steady state.  
F) MHCII expression in Ly6C+CD115+ cells in the BM and blood at steady state.  
Intracellular staining of MHCII or isotype control in the BM and staining of surface MHCII in blood 
of WT Lin-SIRPa+CD115+ cells. Histograms show the percentage of Flt3+ cells within the Lin-
SIRPa+CD115+Ly6C+ MHCII+ and MHCII– cells. 
G) Intracellular expression of MHCII in BM R1, R2 and R3 in WT, pI-/-, pIII+pIV -/-, pIV-/- BM at 
steady state. Percentages of parent indicated above each gate ± SEM.  
H) MHCII expression in total BM and blood Lin-CD115+SIRPα+ cells in pI-/-, pIII+pIV -/-, pIV-/-  and 
Ciita-/-  mice at steady state.  
I) MHCII+ fraction of R2 cells is independent of Flt3L. FACS analysis and quantification in 
percentage of live cells and absolute number of the MHCII+ cells within R2 in the blood of Flt3l-/- and 
Flt3+/+ mice.  
J) MHCII+ fraction of R2 cells is dependent on CCR2. FACS analysis and quantification in 
percentage of live cells and of Ly6C+ monocytes of the MHCII+ cells within R2 in Ccr2-/- and Ccr2+/+ 
mice. Mean ± SEM, *p<0.05, **<0.005, ***p<0.0005, ****p<0.00005, Student’s t-test. 
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Figure S3 (Related to Figure 3): PU1 levels influence the development of R2 monocytes and R3 
pre-DCs.  
A,B) Cellularity of Sfpi1+/+ and Sfpi1+/-  BM, blood and spleen. Quantification of percentage 
in total cells (A) and normalized absolute number (normalized to Sfpi1+/+ controls) (B) of BM 
and blood R1 and R2 monocytes and R3 pre-DCs from Sfpi1+/+ and Sfpi1+/-  mice. Percentage 
of total Ly6ChiMHCII- cells in total splenocytes and the fold change of absolute number of 
R2 over R1 monocytes in the BM and blood of Sfpi1+/+ and Sfpi1+/-  mice. 
C) MHCII+ fraction of R2 is PU.1 – dependent. Percentage of live and absolute number of the 
MHCII+ cells within R2 in the blood of Sfpi1+/+ versus Sfpi1+/- mice.   
D-F) Cellularity of Sfpi1+/+ and Sfpi1+/-  spleen total DCs, CD11b+ DCs and pDCs.  
FACS analysis of the Lin-(CD19-, Ly6G-, CD3e-, NK1.1-, Ter119-, CD45RA-, ckit-) CD11c+MHCII+ 
CD8α+ and CD11b+ DCs (D) ESAMhi- and ESAMlo- CD11b+ DCs (E) and PDCA1+ cells (F) in the 
spleen of Sfpi1+/+ and Sfpi1+/- mice. Histograms in D show the levels of Flt3 in the ESAMhi (solid 
black line) and the ESAMlo DCs (shaded grey) with mean fluorescence intensity (MFI) indicated 
adjacent to the respective histogram.  
G) Percentage in total BM cells of LSK, MDP, CDP, cMop and Pre-DC populations from Sfpi1+/+ and 
Sfpi1+/- mice. 
(Data shown is mean ± SEM, *p<0.05, ***p<0.0005, ns= non-significant; Student’s t-test) 
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Figure S4 (Related to Figure 4): iNOS production is restricted to activated R1 monocytes. 
A) DC lineage tracing of iNOS+ cells. FACS analysis of YFP expression in Lin-CD11b+  iNOS+ and 
iNOS- cells in L.m.-infected Zbtb46Cre x ROSA lsl YFP mice (day2).  
B) MHCII expression in total WT BM after overnight culture with LPS, with or without IFNγ. 
C) In vitro overnight stimulation with L.m. or no stimulation, of R1 and R2 monocytes and pre- DCs 
R3 and P. 
D) Anti-iNOS antibody staining of iNOS-Tomato+ (red cells) and total Lin-CD11b+ cells in ΔActA-
L.m. infected Nos2TomatoCREx ROSAlslTomato mice.  
  
  
Figure S5 (Related to Figure 5): PU.1 inhibits the generation of iNOS+ macrophages upon 
microbial stimulation. 
A) MHCII expression of Ly6C+, Ly6C+iNOS- and Ly6C+iNOS+splenocytes from ΔActA-L.m. 
infected Sfpi1+/+ versus Sfpi1+/- mice. 
B) Mean fluorescence intensity (MFI) of anti-iNOS staining on BMDMs from Sfpi1+/+ and Sfpi1+/- 
mice cultured overnight with plain media, L.m.(MOI of 1 or 10 CFU) or LPS (1ug/ml).  
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Figure S6 (related to Figure 6): PU.1highFlt3+MHCII+ R2 monocytes differentiate into PD-
L2+CD209+ moDCs upon exposure to GM-CSF  
A,B)  Phenotype of blood cells and splenocytes from mice bearing B16 or B16-GMCSF tumours. 
FACS analysis of the Ly6C+MHCII- (blue), Ly6C+MHCII+ (red) Ly6C-MHCII+ (green) cells within 
the Lin-(Ly6G-, CD19-, CD3ɛ-, NK1.1-, Ter119-, CD45RA-, cKit-) CD115+ cells in the blood (A) and 
the Lin- Ly6G-CD11b+ cells in spleen (B) of B16 or B16-GMCSF tumor-bearing mice. FACS staining 
for CD11c and MHCII in Lin-Ly6G- cells of the spleen showing the overlap of Ly6C+MHCII- (blue), 
Ly6C+MHCII+ (red) and Ly6C+MHCII+ (green) cells within the DC gating (B). n= 3-6 mice per group 
(A,B)  (Mean ± SEM;* p<0.05, ns= non-significant; Student’s unpaired t-test.)  
C) Phenotype of lymph nodes after LPS treatment. FACS analysis for FcɣRII/III and CD209a 
expression in the Lin-MHCII-CD11b+ cells of mice treated either with PBS or LPS. CD206 and PDL2 
phenotype of the FcɣRII/III+CD209+, FcɣRII/III+CD209- and the FcɣRII/III-CD209- cells is shown. 
D) Role of CCR2 in GM-CSF-dependent CD11b+MHCII+ splenocytes.   
FACS analysis of FcgRII/III+CD209-, FcgRII/III+CD209+, FcgRII/III-CD209+ and FcgRII/III-CD209- 
in WT and Ccr2-/- mice bearing B16-GMCSF tumors. Percentage in the Lin-CD11b+MHCII+CD4- 
splenocytes of each subset is shown. Mean ± SEM,  * p<0.05, Student’s unpaired t-test. 
E) Phenotype of naïve CD4+ DCs in the spleen. FACS staining of Lin-CD11b+MHCII+CD4+ cells for 
CD115, Flt3, ESAM1, PDL1 (CD274) and PDL2 (CD273) in naïve mice. 
F) Zbtb46Cre x ROSA lslYFP fate mapping.  FACS analysis of YFP expression on Lin-
CD11b+MHCII+CD4+ cells from naïve Zbtb46Cre x ROSA lslYFPmice. Percentage of YFP+ cells within 
Lin-CD11b+MHCII+ subsets from B16-GMCSF-tumour-engrafted Zbtb46Cre x ROSA lslYFPmice.  
G) Endogenous expression of FcɣRII/III and CD209a in Lin-CD11b+MHCII+CD4- cells in the 
tumour-bearing WT (CD45.1) mice adoptively transferred with R1 (CD45.2) or R2 (CD45.2). 
 
 
  
Figure S7 (Related to Figure 7): PU1 influences the number of the PDL2+MHCII+ cells 
generated in vitro in response to GMCSF. 
A) GM-CSF culture of total BM from Sfpi1+/+ and Sfpi1+/- mice.  
FACS analysis for PDL2 (CD273), MHCII and CD86 from DAPI- progeny obtained after 5 days of 
GMCSF culture. Absolute number of PDL2+MHCIIhi and PDL2intMHCIIint cells is quantified in the 
graphs shown. n=4 independent cultures. 
B) Phenotype of adoptively transferred Sfpi1+/+ or Sfpi1+/- whole BM into B16-GMCSF treated 
CD45.1+ congenic recipients. FACS analysis of CD45.1+ (recipient) and CD45.2+ (donor) 
granulocytes (Ly6G+CD11b+) and B cells (Ly6G-CD11b-CD19+ B220+) in B16-GMCSF tumor 
engrafted CD45.1+ mice. 
C) Graphical summary of proposed model. 
 Ly6C+ monocytes consist of 2 subsets- PU1lo R1 and PU1hi R2, that are independently capable of 
developing into different inflammatory progeny. R1 gives rise to FcɣRII/III+CD209a- cells in response 
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to GM-CSF or iNOS+ cells in response to microbial stimulation. R2 produces FcgRII/III+CD209+ mo-
DCs in response to GM-CSF. These different roles are dictated by increased or decreased levels of 
PU.1 expression. 
 
 
Supplemental Experimental Procedures  
 
Mice: C57Bl/6 mice were bought from Charles River Laboratories, UK. Ccr2-/- (Boring et 
al., 1997), Nr4a1-/- (Lee et al., 1995), Sfpi1+/- (McKercher et al., 1996), CD45.1+ 
(JAX:002014) mice were housed within the clean unit of the animal housing facility at 
King’s College London. Zbtb46-GFP mice (Satpathy et al., 2012)were housed at the animal 
facility at Queen Mary, University of London. pIII +pIV-/-: (LeibundGut-Landmann et al., 
2004), pIV-/- (Waldburger et al., 2001), pI-/-  (Dubrot et al., 2014) and Ciita-/- (JAX: 003239) 
micewere housed at Geneva University, Switzerland. All mice maintained under specific 
pathogen-free conditions in accordance with the UK Animals (Scientific Procedures) 
Act,1986. Zbtb46Cre x ROSAloxSTOPloxYFP (Jakob Loshk, 2016)  
, NOS2Tomato-CrexROSAloxSTOPloxtdTomato (Bechade et al., 2014) bone marrow was injected into 
lethally irradiated recipients and used in all experiments as indicated. 
 
Reagents: Complete medium used for cell culture was RPMI (Life technologies) with 
Glutamax, and 10% FBS (Life technologies) and 50uM beta-mercaptoethanol (Sigma). FACS 
buffer used was made of PBS (Life Technologies) with 1% bovine serum albumin (Apollo 
Scientific) and 2mM EDTA. 
 
Bone marrow Chimeras: 8-10 week old C57Bl/6 mice were hematopoietically-lethal 
irradiated with 11Gy; bone marrow from Zbtb46-Cre-loxSTOPloxYFP (Loshko et al, 2016) , 
Zbtb46-iDTR mice (Meredith et al., 2012)or NOS2-Tomato-CrexROSAloxSTOPloxtdTomato 
(Bechade et al., 2014) was injected intravenously at a dose of 5 x 106 cells in100ul into these 
irradiated recipients. To allow full reconstitution, the mice were used at 8-16 weeks after 
transplantation. Ccr2-/- (CD45.2+) and WT (CD45.1+) mixed bone marrow chimeras were 
produced in hematopoietically-lethal irradiated (11Gy) CD45.1+ recipients that received 
CD45.1+ WT and Ccr2-/- (CD45.2+) bone marrow in equal parts. CD45.1+ recipients that 
received 100%CD45.2+ C57Bl/6 bone morrow were used as a control for the complete 
replacement of recipient bone marrow with donor-derived bone marrow. 
 
FACS Reagents: Fluorochrome or biotin- conjugated antibodies were used to stain single 
cell suspensions for flow cytometry. These included monoclonal antibodies specific to mouse 
CD19 (Clone MB19-1), Ly6G (Clone: 1A8),CD3ɛ (Clone 145-2C11), Ter119 (Clone 
Ter119), NK1.1 (Clone PK136), CD45RA (Clone: HI100), ckit (Clone:2B8), MHCII I-A/I-E 
(Clone: M5/114. 15.2), Ly6C (clone: HK1.4), CD11b (clone:M1/70), CD115 (clone:AFS98), 
CD16/32 (clone: 93), CD209 (clone: LW206), CD135 (clone A2F10), CD172a (clone: P84), 
CD11c (clone: N418), CD273 (clone: TY25), CD274 (clone:10F.9G2) that were bought from 
eBioscience (Hatfield, UK) and Biolegend (London, UK). For staining intracellular levels of 
iNOS, cells were fixed and permeabilized using BD Cytofix/Cytoperm Fixation kit as per 
manufacturer’s instructions and stained with anti-iNOSA488 or -iNOS-PE (clone: CXNFT) 
purchased from eBioscience. For staining PU.1, cells were fixed and permeabilized using 
FoxP3/ Transcription factor staining buffer set (eBioscience) according to manufacturer’s 
instructions. Anti-PU.1 rabbit monoclonal antibody (clone: 9G7) and the corresponding 
isotype were purchased from Cell Signaling Technology (New England Biolabs (UK) Ltd). 
 
Cell sorting by flow cytometry 
For sorting, bone marrow or spleen cells were resuspended to an approximate concentration 
of 7000cells/ul. They were then sorted on a BD FACS Aria (special order machine) fitted 
with 405nm, 488nm, 561nm, 633nm lasers and sorted through 100um nozzle with 4-way 
purity. Purity checks were run on samples used for microarrays and were used when purity 
was found to be >95%. Both instruments were housed at the Biomedical Research Centre 
Flow Core Facility (Guy’s and St Thomas’ NHS Foundation Trust and King’s College 
London). Flow cytometry analysis was done using FlowJo software (TreeStar). 
 
Giemsa Staining: Cytospins of FACS sorted R1, R2, R3 and P were fixed with methanol for 
5 mins, stained with 1:20 Giemsa stain in deionized water for 45 mins and then washed and 
air dried. Slides were imaged on Motic AE2000 with 40x magnification. Images were 
modified for brightness with ImageJ (NIH). 
 
In vitro L.m. infections: In vitro cultures of primary sorted cells with Listeria monocytogenes 
(L.m.) was done overnight at an MOI of 0.01 or 0.1 as indicated in complete RPMI1640 
medium supplemented with MCSF (20ng/ml) (Peprotech), GMCSF(3ng/ml) (Peprotech) and 
human Flt3L(100ng/ml) (CellDex). BMDMs were derived from Sfpi1+/- or Sfpi1+/+ BM 
cultured for 8-10 days in DMEM medium (Life technologies) supplemented with 10% FBS 
and 10% MCSF containing L-929 cell culture supernatant. These were re-plated as 0.45 x 106 
cells/well in a 24-well non-tissue culture treated plate to be stimulated with LPS (1ug/ml) or 
L.m. at MOI 1 or 10 for 16 hours. Cells were collected, stained with fluorochrome conjugated 
antibodies and analysed by FACS. 
 
B16-GMCSF tumor experiments: Melanoma cell lines B16 and B16 expressing GMCSF 
(B16-GMCSF)(Dranoff et al., 1993) were maintained in RPMI1640 medium supplemented 
with Glutamax (Life technologies), 10% fetal bovine serum (Life technologies), 1% 
penicillin-streptomycin (Life Techonologies) and 50uM beta-mercaptoethanol (Sigma) and 
used from between passages 4 and 10. Cells were checked for viability with Trypan Blue and 
1.5-3 x 105 live cells were injected subcutaneously in sterile RPMI 1640 medium alone. 
 Infection. Listeria monocytogenes (L.m.) or the ΔActA mutant of the same (ΔActA Listeria) 
were grown and sub-cultured in brain heart infusion broth at 370C until an OD600 value of 
0.12-0.15 was obtained to use bacteria in their exponential growth phase. 4 – 5 x 103 wild 
type CFU (Listeria) or 106 ΔActA mutant CFU of Listeria monocytogenes were injected 
intravenously in sterile PBS. 
 
Microarray processing and analysis:  
Affymetrix CEL files were converted into gct files using the ExpressionFileCreator Module 
within Gene Pattern Software (Broad Institute) (Reich et al., 2006). The RMA algorithm 
withquantile normalization and background correction was used. No thresholds or filters were 
applied for assessing the relative expression of all genes assayed on the microarray. Heat 
maps were generated with this data on Gene-E software.  
To create the Volcano plots, Mutiplot Preprocess Module within the Gene Pattern Software 
(Broad Institute) was used to derive fold change and p-values from the expression dataset of 
the aforementioned microarrays to be used in the MultiplotVisualizer Module. This latter 
module was used to highlight the genes more highly expressed in R2 or R3 above a threshold 
of p-value set at 0.05 and fold change of 1.2. These selected genes were then overlaid on 
comparisons done between R1 and R2, and R1 and R3 to obtain the plots shown in Fig.1F. 
PCA analysis and hierarchical clustering: Microarray data of R1, R2 and R3 were 
compared with ST1.0 array data available on ImmGEN for Pre-DCs (GSE68590) ) 
(Tussiwand et al., 2015) (and CDP (GSE 15907) (www.immgen.org) on Qlucore Omics 
Explorer (Sweden) and plotted as 2D plots on Prism (Graphpad).  Hierarchical clustering of 
data sets was performed using Gene-E software (Broad Institute). 
 
qPCR Primers: Cells were sorted as described and centrifuged. Supernatant was removed 
and cells were resuspended in RLT buffer from the RNeasy kit (Qiagen). mRNA was 
extracted using the columns as per manufacturer’s instructions. mRNA was resuspended in 
RNase-free water and the concentration and quality measured by nanodrop (Thermo 
Scientific). Equal amounts of mRNA (between 0.1ng – 5ug) from each sample were taken to 
produce cDNA using the manufacturer’s First Strand cDNA synthesis protocol with the 
RevertAid™  H minus Reverse Transcriptase (Thermo Scientific). Random Primers (Oligo 
dT primers) were mixed with template RNA and incubated at 65oC for 5 mins and Ribolock 
(Thermo Scientific), dNTP mix, Reaction buffer (5x) and mMulV reverse transcriptase 
enzyme were added and incubated at RT for 10 mins, 42oC for 1hr and at 70oC for 5 mins to 
inactivate the enzyme. A 1 in 10 dilution of this cDNA was used to perform qPCR with 
Sensimix™SYBR® (Bioline) as per manufacturer’s instructions.  
 
Multidimensional reduction analysis: Automated t-distributed stochastic non-linear 
embedding (t-SNE) algorithm was used to visually (viSNE) analyse (Amir el et al., 2013) 
bone marrow monocytes acquired by FACS for 7 fluorochromes. The online (web-based) 
software implementation of viSNE (Cytobank) (Kotecha et al., 2010) was used to analyse the 
presence of different populations within the Ly6ChiCD115+ BM monocytes. No a priori 
gating was used and an unbiased automated analysis was conducted. The resulting viSNE 
maps were overlaid with each monocyte population, R1, R2 and pre-DC R3 that were gated 
separately by conventional FACS analysis. The colour scheme for all four viSNE maps was 
adjusted to represent the Flt3 expression – blue colour denoting lower levels and red – 
higher.  
  
Single cell qPCR: Single cells were FACS sorted from bone marrow into 9ul of Cell Direct 
pre-Amp master mix in 96-well qPCR plates. Complementary DNA (cDNA) synthesis and 
specific target amplification of 45 genes (including 3 housekeeping genes- Hprt, ActB, Gapdh) 
was performed using CellsDirect One Step qRT-PCR kit (Invitrogen) with 48 Taqman assays 
(Life technologies) at 0.2x. Reverse transcription was performed within the same plates using 
the following cycle: 400C for15 mins, 500C for 15 mins, 600C for 15 mins. Enzyme inactivation 
was done at 950C for 2mins followed by 22x (950C for 15s, 600C for 4mins). cDNA was then 
diluted 1 in 5 in low EDTA TE buffer. Samples were stored at -200C until used in the BioMark. 
81 cells of R2, and 44 cells of R1 and R3 each were compared along with control well including 
10 cells and no cell controls and dilutions of cDNA from 105 cells to 1 cells to check for primer 
viability. 5ul of diluted cDNA + Taqman mastermix + Sample loading reagent and 5 ul of each 
Taqman assay + Assay loading reagent were loaded into their respective wells on 4 M48.M48 
Dynamic Arrays. Samples and Assays were then loaded into the reaction chambers of the 
Dynamic Array using the IFC ControllerMX (Fluidigm), and then transferred to the BioMark 
HD for qPCR (95◦C for 10 min; 40 cycles of 95◦C for 15 s and 60 ◦C for 60 s). Data obtained 
from the ‘Real time PCR analysis’ software (Fluidigm) was analysed using Gene-E software. 
  
 The following Taqman probes were tested on all samples. 
 
  Primers 
Adamts3 Mm00625880_m1 
Cd209a Mm00460067_m1 
Cd209c Mm00652419_m1 
Cd209d Mm00459972_m1 
Cd209e Mm00459980_m1 
Cd74 Mm01262763_m1 
Ciita Mm00482914_m1 
Clec10a Mm00546124_m1 
Clec4a2 Mm00488795_m1 
Clec4g Mm01212425_m1 
Clec5a Mm01131766_m1 
Clec7a Mm00490960_m1 
Clec9a Mm00554956_m1 
Csf1r Mm01266652_m1 
Csf2ra Mm00438331_g1 
Csf2rb Mm00655745_m1 
Csf3r Mm00432735_m1 
Ctsb Mm01310506_m1 
CtsG Mm00456011_m1 
Cybb Mm01287743_m1 
Fcgr2b Mm00438879_m1 
Fcgr3 Mm00438882_m1 
Fcgr4 Mm00519988_m1 
Flt3 Mm00439016_m1 
H2-Aa Mm00439211_m1 
H2-Ab1 Mm01271199_m1 
H2-dma Mm04337015_m1 
H2-dMb2 Mm00783707_s1 
Id2 Mm00711781_m1 
Irf8 Mm00492567_m1 
Klrb1f Mm04211785_m1 
Klrd1 Mm00495182_m1 
Kmo Mm01321343_m1 
Mgl2 Mm01250813_m1 
Mpo Mm01298424_m1 
Mrc1 Mm00485155_m1 
Ms4a3 Mm00460072_m1 
Nfil3 Mm00600292_s1 
Sfpi1 Mm00488140_m1 
Spib Mm03048233_m1 
Tcfec Mm01161234_m1 
Zbtb46 Mm00511327_m1 
These genes were selected for their discriminating capacity based on the PCA analysis between 
sorted populations of R1, R2 and R3 along with genes with previously described expression in 
monocytes and DCs.  
 
 
Statistical Analysis. Data was analysed for statistical significance by unpaired Student’s t-
test. Differences were considered significant for p<0.05. *p<0.05, **p<0.005, ***p<0.0005, 
****p<0.00005. 
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